| Description | AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties. |
| In vivo | AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice. AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rats. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high-fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats[1]. |
| Cell experiments | The lipid-lowering profile in rodents AZ-1355, A New Dibenzoxazepine Derivative |
| Animal experiments | AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice. AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rats. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high-fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. |
| molecular weight | 299.32 |
| Molecular formula | C17H17NO4 |
| CAS | 75451-07-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 22.5 mg/mL (75.17 mM) |
| References | 1. Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40(3-4):263-71. |